Human factors validation study of a disposable autoinjector (Bmab 1200 autoinjector) for subcutaneous delivery of Ustekinumab.
Ustekinumab is approved for treating moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. The Bmab 1200 autoinjector is a simple, two-step device for subcutaneous ustekinumab biosimilar delivery. This was an in vitro, nonclinical, simulated-use human fac…
ADAR1 loss-of-function variants altering RNA editing define a new interferon-dependent psoriasis subtype.
Recent evidence implicates altered RNA editing and dysregulated type I IFN signaling in immune-mediated diseases, including psoriasis, although the underlying genetic mechanisms remain poorly defined. We investigated four unrelated multiplex families with early-onset plaque psoriasis, with or withou…
Risk of Cancer according to Duration of Targeted Therapy Exposure in Spondyloarthritis: A Nationwide Cohort Study from the French Health Insurance Database.
To assess the association between duration of targeted therapy exposure and cancer risk in patients with spondyloarthritis (SpA), including those with psoriatic arthritis, axial SpA, and other subtypes. This nationwide cohort study used the French health insurance database to identify adults with Sp…
Clinical field tests to evaluate cardiorespiratory fitness in psoriatic arthritis.
Cardiorespiratory fitness (CRF) is reduced in patients with psoriatic arthritis (PsA), highlighting the need for a consistent assessment of CRF in clinical practice. This study aimed to examine the associations between outcomes of clinical field tests, namely six-minute walk test (6MWT) and handgrip…
Evolving Economic Burden of Spondyloarthritis (2015-2023): A Nationwide Analysis of Direct and Indirect Costs.
To assess temporal changes in the direct and indirect economic burden of spondyloarthritis (SpA), including psoriatic arthritis (PsA), in France between 2015 and 2023 using nationwide healthcare data. We conducted a retrospective population-based study using the French National Health Data System (S…
Experimental models of spondyloarthritis: Pathophysiological insights and translational challenges.
Spondyloarthritis (SpA) represents a heterogeneous group of chronic inflammatory rheumatologic diseases, including axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), and SpA associated with inflammatory bowel disease (IBD). These conditions share overlapping clinical manifestations, genetic…
Distinct Cardiac Profiles in Psoriatic Arthritis and Rheumatoid Arthritis: Insights from Echocardiographic Findings.
Cardiovascular disease contributes to morbidity and mortality in rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Systemic inflammation drives risk in RA, while PsA may involve additional immune-metabolic mechanisms, potentially resulting in distinct cardiac phenotypes. Comparative data on s…
Efficacy and safety of golimumab biosimilar BAT2506 in patients with active psoriatic arthritis after switching from reference golimumab: 52-week results of a phase 3, double-blind, randomized study.
Switching from a reference biologic to a biosimilar can offer patients similar safety and efficacy while reducing healthcare costs and increasing treatment access. We report long-term efficacy and safety while switching from reference golimumab (Simponi; Ref-GLM) to BAT2506 in patients with active p…